This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
The study was a prospective, randomised trial that was conducted in a single centre. The method of randomisation was not reported and it was unclear whether blinding took place. The duration of follow-up was one year. No loss to followup was reported.
Analysis of effectiveness
The analysis of the clinical study was conducted on an intention to treat basis. The primary health outcomes were readmission, with cause classified by a clinician blinded to the treatment allocation, or death. The secondary end points included the number of all-cause, HF and HF-related readmissions, or other cardiovascular disease (CVD)-related readmissions. The two groups were compared using Mantel-Haenszel chi-squared, relative risks (RR) and log-rank tests. Sub-group analyses, stratified by cause of readmission, and analyses of outcomes adjusted for early mortality were conducted. A Cox proportional-hazards model was used to assess readmission-free survival. Adjustments for clinical and demographic characteristics were made.
Effectiveness results
For the primary outcome of readmission or death, 25 patients (56.8%) in the intervention group and 36 patients (81.8%) in the control group had at least one readmission or died during the follow-up (RR 0.69; 95% confidence interval, CI: 0.52 -0.92, p=0.01).
There was a 39% reduction in all-cause readmissions in the intervention group compared with the control group. There were 49 in the intervention group versus 80 in the control group, (p=0.06).
Twenty-two patients (50.0%) in the intervention group and 35 patients (79.6%) in the control group experienced HF or other CVD readmission or death (RR 0.63, 95% CI: 0.46 -0.86, p=0.004).
After adjusting for clinical and demographic characteristics, the intervention group had a significantly lower risk of allcause readmission or death (hazard ratio, HR, 0.56, 95% CI: 0.32 -0.96, p=0.03) in comparison with the control group. The intervention group also had a lower risk of HF or other CVD readmission or death (HR 0.51, 95% CI: 0.29 -0.90, p=0.02), and a lower risk of HF readmission or death (HR 0.52, 95% CI: 0.28 -0.98, p=0.04).
Clinical conclusions
A formal education and support intervention substantially reduced adverse clinical outcomes.
Measure of benefits used in the economic analysis
The authors did not develop a summary benefit measure. A cost-consequences analysis was therefore conducted.
